HCM
HUTCHMED Achieves Strong Growth in 2025 Despite Global Headwinds
HUTCHMED, a biopharmaceutical company dedicated to developing innovative cancer therapies, has reported a strong performance in 2025 despite facing global headwinds. According to the company's recent conference call transcript, HUTCHMED achieved significant growth in its ex-China sales and rebounded in China oncology products sales. Notably, the company'